VEGFA (vascular endothelial growth factor A)

2003-02-01  

Identity

HGNC
LOCATION
6p21.1
LOCUSID
ALIAS
MVCD1,VEGF,VPF
FUSION GENES

Other Information

Locus ID:

NCBI: 7422
MIM: 192240
HGNC: 12680
Ensembl: ENSG00000112715

Variants:

dbSNP: 7422
ClinVar: 7422
TCGA: ENSG00000112715
COSMIC: VEGFA

RNA/Proteins

Gene IDTranscript IDUniprot
ENSG00000112715ENST00000230480A2A2V4
ENSG00000112715ENST00000324450A0A0A0MR43
ENSG00000112715ENST00000372055J3KPA4
ENSG00000112715ENST00000372064A0A0A0MRQ4
ENSG00000112715ENST00000372067H3BLW8
ENSG00000112715ENST00000372077P15692
ENSG00000112715ENST00000413642A0A0A0MSI7
ENSG00000112715ENST00000417285A0A0A0MSH7
ENSG00000112715ENST00000425836A0A0A0MSH5
ENSG00000112715ENST00000457104P15692
ENSG00000112715ENST00000482630A0A0A0MTB2
ENSG00000112715ENST00000518689P15692
ENSG00000112715ENST00000518824P15692
ENSG00000112715ENST00000519767H0YBZ0
ENSG00000112715ENST00000520265H0YBI8
ENSG00000112715ENST00000520948P15692
ENSG00000112715ENST00000520948A0A024RD37
ENSG00000112715ENST00000523125P15692
ENSG00000112715ENST00000523873P15692
ENSG00000112715ENST00000523873A0A024RD33
ENSG00000112715ENST00000523950P15692
ENSG00000112715ENST00000523950A0A0Y0IMM4

Expression (GTEx)

0
100
200
300
400
500
600
700

Pathways

PathwaySourceExternal ID
Cytokine-cytokine receptor interactionKEGGko04060
VEGF signaling pathwayKEGGko04370
Focal adhesionKEGGko04510
Renal cell carcinomaKEGGko05211
Pancreatic cancerKEGGko05212
Bladder cancerKEGGko05219
Cytokine-cytokine receptor interactionKEGGhsa04060
VEGF signaling pathwayKEGGhsa04370
Focal adhesionKEGGhsa04510
Pathways in cancerKEGGhsa05200
Renal cell carcinomaKEGGhsa05211
Pancreatic cancerKEGGhsa05212
Bladder cancerKEGGhsa05219
Rheumatoid arthritisKEGGko05323
Rheumatoid arthritisKEGGhsa05323
PI3K-Akt signaling pathwayKEGGhsa04151
PI3K-Akt signaling pathwayKEGGko04151
HIF-1 signaling pathwayKEGGhsa04066
Proteoglycans in cancerKEGGhsa05205
Proteoglycans in cancerKEGGko05205
MicroRNAs in cancerKEGGhsa05206
MicroRNAs in cancerKEGGko05206
Ras signaling pathwayKEGGhsa04014
Rap1 signaling pathwayKEGGhsa04015
Rap1 signaling pathwayKEGGko04015
Immune SystemREACTOMER-HSA-168256
Cytokine Signaling in Immune systemREACTOMER-HSA-1280215
Signaling by InterleukinsREACTOMER-HSA-449147
HemostasisREACTOMER-HSA-109582
Platelet activation, signaling and aggregationREACTOMER-HSA-76002
Response to elevated platelet cytosolic Ca2+REACTOMER-HSA-76005
Platelet degranulationREACTOMER-HSA-114608
Signal TransductionREACTOMER-HSA-162582
Signaling by VEGFREACTOMER-HSA-194138
VEGF ligand-receptor interactionsREACTOMER-HSA-194313
VEGF binds to VEGFR leading to receptor dimerizationREACTOMER-HSA-195399
VEGFA-VEGFR2 PathwayREACTOMER-HSA-4420097
VEGFR2 mediated cell proliferationREACTOMER-HSA-5218921
Gene ExpressionREACTOMER-HSA-74160
Generic Transcription PathwayREACTOMER-HSA-212436
Developmental BiologyREACTOMER-HSA-1266738
Axon guidanceREACTOMER-HSA-422475
EPH-Ephrin signalingREACTOMER-HSA-2682334
EPHA-mediated growth cone collapseREACTOMER-HSA-3928663
Cellular responses to stressREACTOMER-HSA-2262752
Cellular response to hypoxiaREACTOMER-HSA-2262749
Regulation of Hypoxia-inducible Factor (HIF) by oxygenREACTOMER-HSA-1234174
Regulation of gene expression by Hypoxia-inducible FactorREACTOMER-HSA-1234158
AGE-RAGE signaling pathway in diabetic complicationsKEGGko04933
AGE-RAGE signaling pathway in diabetic complicationsKEGGhsa04933
EGFR tyrosine kinase inhibitor resistanceKEGGko01521
EGFR tyrosine kinase inhibitor resistanceKEGGhsa01521
Transcriptional regulation by the AP-2 (TFAP2) family of transcription factorsREACTOMER-HSA-8864260
TFAP2 (AP-2) family regulates transcription of growth factors and their receptorsREACTOMER-HSA-8866910
Interleukin-4 and 13 signalingREACTOMER-HSA-6785807
Fluid shear stress and atherosclerosisKEGGko05418
Fluid shear stress and atherosclerosisKEGGhsa05418

Protein levels (Protein atlas)

Not detected
Low
Medium
High

PharmGKB

Entity IDNameTypeEvidenceAssociationPKPDPMIDs
PA128406956fluorouracilChemicalClinicalAnnotationassociatedPD20125120, 24090479, 25955730
PA130232992bevacizumabChemicalClinicalAnnotation, PathwayassociatedPD20124951, 20125120, 23149126, 23953100, 25955730, 26100253, 27139155
PA131285527oxaliplatinChemicalClinicalAnnotationassociatedPD20125120, 24090479, 25955730
PA134850558Macular DegenerationDiseaseClinicalAnnotationassociatedPD22840423, 23149126, 23559864, 23570466, 23842101
PA150481189taxanesChemicalClinicalAnnotationassociatedPD26194361
PA162372840sunitinibChemicalClinicalAnnotationassociatedPD22948895
PA164746012ranibizumabChemicalClinicalAnnotationassociatedPD22840423, 23149126, 23559864, 23570466, 23842101, 23953100
PA164771236pegaptanibChemicalClinicalAnnotationassociatedPD23953100
PA166114377hand-foot syndromeDiseaseClinicalAnnotationassociatedPD22736425
PA166114943regorafenibChemicalLabelAnnotationassociated
PA166118342afliberceptChemicalPathwayassociated20124951
PA28180FLT1GenePathwayassociated20124951
PA30086KDRGenePathwayassociated20124951
PA31783NRP1GenePathwayassociated20124951
PA443560Breast NeoplasmsDiseaseClinicalAnnotationassociatedPD24061601, 25111199, 25955730, 26100253, 27139155
PA443624Carcinoma, Renal CellDiseaseClinicalAnnotationassociatedPD
PA444447Carcinoma, HepatocellularDiseaseClinicalAnnotationassociatedPD22736425, 24510746
PA444552HypertensionDiseaseClinicalAnnotationassociatedPD26002049
PA444606Erectile DysfunctionDiseaseClinicalAnnotationassociatedPD23007311
PA445204Ovarian NeoplasmsDiseaseClinicalAnnotationassociatedPD26194361
PA445425Prostatic NeoplasmsDiseaseClinicalAnnotation, VariantAnnotationambiguousPKPD23860526, 25111199
PA445742Stomach NeoplasmsDiseaseClinicalAnnotationassociatedPD24090479
PA446108Colorectal NeoplasmsDiseaseClinicalAnnotationassociatedPD20125120, 25955730, 26100253, 27139155
PA446974Choroidal NeovascularizationDiseaseClinicalAnnotationassociatedPD23953100
PA448771capecitabineChemicalClinicalAnnotationassociatedPD20125120, 25955730
PA448803carboplatinChemicalClinicalAnnotationassociatedPD26194361
PA448871celecoxibChemicalPathwayassociated22336956
PA449014cisplatinChemicalClinicalAnnotationassociatedPD24090479
PA449165cyclophosphamideChemicalClinicalAnnotation, VariantAnnotationambiguousPD23860526, 25111199
PA449383docetaxelChemicalClinicalAnnotationassociatedPD24061601, 25111199, 26100253
PA449456enalaprilChemicalClinicalAnnotationassociatedPD26002049
PA450085irinotecanChemicalClinicalAnnotationassociatedPD20125120, 25955730
PA450198leucovorinChemicalClinicalAnnotationassociatedPD20125120, 25955730
PA451346sildenafilChemicalClinicalAnnotationassociatedPD23007311
PA7000sorafenibChemicalClinicalAnnotationassociatedPD22736425, 24510746

References

Pubmed IDYearTitleCitations
209356292010Meta-analysis identifies 13 new loci associated with waist-hip ratio and reveals sexual dimorphism in the genetic basis of fat distribution.396
119603722002Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis.374
203831462010New loci associated with kidney function and chronic kidney disease.337
190203232008Genotype score in addition to common risk factors for prediction of type 2 diabetes.304
242631902013VEGF targets the tumour cell.292
172051202006MiRNA-directed regulation of VEGF and other angiogenic factors under hypoxia.246
175919532007Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury.226
177854332007Hypoxia-inducible factor 1 and dysregulated c-Myc cooperatively induce vascular endothelial growth factor and metabolic switches hexokinase 2 and pyruvate dehydrogenase kinase 1.215
192341312009Endothelial expression of autocrine VEGF upon the uptake of tumor-derived microvesicles containing oncogenic EGFR.212
227895362012VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex.209

Citation

Dessen P

VEGFA (vascular endothelial growth factor A)

Atlas Genet Cytogenet Oncol Haematol. 2003-02-01

Online version: http://atlasgeneticsoncology.org/gene/42787/vegfa